215 related articles for article (PubMed ID: 10630360)
41. Intracellular accumulation and cytotoxicity of doxorubicin with different pharmaceutical formulations in human cancer cell lines.
Serpe L; Guido M; Canaparo R; Muntoni E; Cavalli R; Panzanelli P; Della Pepal C; Bargoni A; Mauro A; Gasco MR; Eandi M; Zara GP
J Nanosci Nanotechnol; 2006; 6(9-10):3062-9. PubMed ID: 17048519
[TBL] [Abstract][Full Text] [Related]
42. [Restorative effect of quercetin on subcellular distribution of daunorubicin in multidrug resistant leukemia cell lines K562/ADM and HL-60/ADM].
Cai X; Chen FY; Han JY; Gu CH; Zhong H; Ouyang RR
Ai Zheng; 2004 Dec; 23(12):1611-5. PubMed ID: 15601547
[TBL] [Abstract][Full Text] [Related]
43. Development of drug resistance is reduced with idarubicin relative to other anthracyclines.
Hargrave RM; Davey MW; Davey RA; Kidman AD
Anticancer Drugs; 1995 Jun; 6(3):432-7. PubMed ID: 7670142
[TBL] [Abstract][Full Text] [Related]
44. Molecular mechanism study of chemosensitization of doxorubicin-resistant human myelogenous leukemia cells induced by a composite polymer micelle.
Han M; Diao YY; Jiang HL; Ying XY; Chen DW; Liang WQ; Gao JQ
Int J Pharm; 2011 Nov; 420(2):404-11. PubMed ID: 21945184
[TBL] [Abstract][Full Text] [Related]
45. Relation between MDR1 mRNA levels, resistance factor, and the efficiency of P-glycoprotein-mediated efflux of pirarubicin in multidrug-resistant K562 sublines.
Meesungnoen J; Jay-Gerin JP; Mankhetkorn S
Can J Physiol Pharmacol; 2002 Nov; 80(11):1054-63. PubMed ID: 12489924
[TBL] [Abstract][Full Text] [Related]
46. Recovery of drug sensitivity by MS-209, a new multidrug resistance-reversing agent, on acute myelogenous leukaemic blasts and K562 cells resistant to adriamycin cell line.
Wang YH; Motoji T; Motomura S; Shiozaki H; Tsuruo T; Mizoguchi H
Eur J Haematol; 1997 Mar; 58(3):186-94. PubMed ID: 9150713
[TBL] [Abstract][Full Text] [Related]
47. Effect of anthracycline analogs on photolabelling of p-glycoprotein by [125I]iodomycin and [3H]azidopine: relation to lipophilicity and inhibition of daunorubicin transport in multidrug resistant cells.
Friche E; Demant EJ; Sehested M; Nissen NI
Br J Cancer; 1993 Feb; 67(2):226-31. PubMed ID: 8094288
[TBL] [Abstract][Full Text] [Related]
48. Reversal effect of substituted 1,3-dimethyl-1H-quinoxalin-2-ones on multidrug resistance in adriamycin-resistant K562/A02 cells.
Sun LR; Li X; Cheng YN; Yuan HY; Chen MH; Tang W; Ward SG; Qu XJ
Biomed Pharmacother; 2009 Mar; 63(3):202-8. PubMed ID: 18818047
[TBL] [Abstract][Full Text] [Related]
49. Simultaneous treatment with 1-beta-D-arabinofuranosylcytosine and daunorubicin induces cross-resistance to both drugs due to a combination-specific mechanism in HL60 cells.
Takemura H; Urasaki Y; Yoshida A; Fukushima T; Ueda T
Cancer Res; 2001 Jan; 61(1):172-7. PubMed ID: 11196156
[TBL] [Abstract][Full Text] [Related]
50. Cellular uptake, cytotoxicity, and transport kinetics of anthracyclines in human sensitive and multidrug-resistant K562 cells.
Praet M; Stryckmans P; Ruysschaert JM
Biochem Pharmacol; 1996 May; 51(10):1341-8. PubMed ID: 8787550
[TBL] [Abstract][Full Text] [Related]
51. The efficacy of WGA modified daunorubicin anti-resistant liposomes in treatment of drug-resistant MCF-7 breast cancer.
Liu S; Song XL; Wang YH; Wang XM; Xiao Y; Wang X; Cheng L; Li XT
J Drug Target; 2017 Jul; 25(6):541-553. PubMed ID: 28277825
[TBL] [Abstract][Full Text] [Related]
52. Comparison of mechanisms responsible for resistance to idarubicin and daunorubicin in multidrug resistant LoVo cell lines.
Toffoli G; Simone F; Gigante M; Boiocchi M
Biochem Pharmacol; 1994 Nov; 48(10):1871-81. PubMed ID: 7986198
[TBL] [Abstract][Full Text] [Related]
53. Kinetics of anthracycline efflux from multidrug resistance protein-expressing cancer cells compared with P-glycoprotein-expressing cancer cells.
Marbeuf-Gueye C; Broxterman HJ; Dubru F; Priebe W; Garnier-Suillerot A
Mol Pharmacol; 1998 Jan; 53(1):141-7. PubMed ID: 9443942
[TBL] [Abstract][Full Text] [Related]
54. C-phycocyanin to overcome the multidrug resistance phenotype in human erythroleukemias with or without interaction with ABC transporters.
Fernandes E Silva E; Figueira FS; Cañedo AD; Machado KS; Salgado MTSF; Silva TK; Wagner EF; Mattozo FH; Lima ÉA; Sales-Neto JM; Ferreira VU; Comitre AA; Mascarenhas SR; Kalil SJ; Votto APS
Biomed Pharmacother; 2018 Oct; 106():532-542. PubMed ID: 29990841
[TBL] [Abstract][Full Text] [Related]
55. Efficacy of multi-functional liposomes containing daunorubicin and emetine for treatment of acute myeloid leukaemia.
Myhren L; Nilssen IM; Nicolas V; Døskeland SO; Barratt G; Herfindal L
Eur J Pharm Biopharm; 2014 Sep; 88(1):186-93. PubMed ID: 24747809
[TBL] [Abstract][Full Text] [Related]
56. Pegylated phosphotidylethanolamine inhibiting P-glycoprotein expression and enhancing retention of doxorubicin in MCF7/ADR cells.
Wang J; Qu H; Jin L; Zeng W; Qin L; Zhang F; Wei X; Lu W; Zhang C; Liang W
J Pharm Sci; 2011 Jun; 100(6):2267-77. PubMed ID: 21246559
[TBL] [Abstract][Full Text] [Related]
57. Effect of magnetic nanoparticles of Fe3O4 and wogonin on the reversal of multidrug resistance in K562/A02 cell line.
Cheng J; Cheng L; Chen B; Xia G; Gao C; Song H; Bao W; Guo Q; Zhang H; Wang X
Int J Nanomedicine; 2012; 7():2843-52. PubMed ID: 22745547
[TBL] [Abstract][Full Text] [Related]
58. A comparative analysis of the sensitivity of multidrug resistant (MDR) and non-MDR cells to different anthracycline derivatives.
Michieli M; Michelutti A; Damiani D; Pipan C; Raspadori D; Lauria F; Baccarani M
Leuk Lymphoma; 1993 Feb; 9(3):255-64. PubMed ID: 8097129
[TBL] [Abstract][Full Text] [Related]
59. Modulator activity of PSC 833 and cyclosporin-A in vincristine and doxorubicin-selected multidrug resistant murine leukemic cells.
Lopes EC; Scolnik M; Alvarez E; Hajos SE
Leuk Res; 2001 Jan; 25(1):85-93. PubMed ID: 11137565
[TBL] [Abstract][Full Text] [Related]
60. Dexrazoxane significantly impairs the induction of doxorubicin resistance in the human leukaemia line, K562.
Sargent JM; Williamson CJ; Yardley C; Taylor CG; Hellmann K
Br J Cancer; 2001 Apr; 84(7):959-64. PubMed ID: 11286477
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
